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Abstract
HIV quasispecies was analysed in plasma and proviral genomes hosted by duodenal mucosa and peripheral blood cells (PBMC) from patients
with early or chronic infection, with respect to viral heterogeneity, tropism compartmentalization and extent of immune activation.
Seventeen HIV-1-infected combined antiretroviral therapy naive patients were enrolled (11 early infection and six chronic infection). V3 and
nef genomic regions were analysed by ultra-deep pyrosequencing. Sequences were used to infer co-receptor usage and to construct
phylogenetic trees. As markers of immune activation, plasma sCD14 and soluble tumour necrosis factor receptor II (sTNFRII) levels were
measured. Median diversity of HIV RNA was lower in patients with early infection versus chronic infection patients. Overall, direct
correlation was observed between V3 diversity and X4 frequency; V3 diversity of HIV RNA was inversely correlated with CD4 T-cell count;
median sCD14 and sTNFRII values were similar in early and chronic patients, but X4 frequency of HIV RNA was directly correlated with
plasma sCD14. The proportion of patients harbouring X4 variants and median intra-patient X4 frequency of proviral genomes tended to be
higher in chronic infection than early infection patients. More pronounced compartmentalization of proviral quasispecies in gut compared
with PBMC samples was observed in patients with early infection compared with chronic patients. The loss of gut/PBMC
compartmentalization in more advanced stages of HIV infection was conﬁrmed by longitudinal observation. More studies are needed to
understand the pathogenetic signiﬁcance of early HIV quasispecies compartmentalization and progressive intermixing of viral variants in
subsequent phases of the infection, as well as the role of immune activation in tropism switch.
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Infection with HIV-1 typically involves the interaction between
the viral envelope glycoprotein gp120 and the CD4 molecule,
followed by interaction with a chemokine receptor, usually
CCR5 or CXCR4. CCR5-using (R5) viruses predominate in
the early stages of HIV-1 infection, whereas a switch towards
CXCR4 usage (X4 viruses) may occur at later stages. While
the propensity to X4 switch varies according to HIV clade, the
presence of X4 variants is invariably associated with a faster
disease progression [1]. Several studies, based on either
phenotypic tests or bulk sequencing, suggest that up to 19.2%
of acutely infected patients may harbour X4 variants [2–6].
Thanks to the newly introduced ultra-deep pyrosequencing
(UDPS), which allows high-resolution analysis of viral quasi-
species, recently it has been shown that the proportion of
patients with primary infection harbouring X4 variants is larger
than previously anticipated [7]. In addition, these technologies
allow us to quantify the relative frequency of even rare variants
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with different co-receptor usage, as compared with the
dominant virus population [8–11]. In a recent study, about
half of acutely infected patients were shown to harbour X4
strains by UDPS, with highly variable intra-patient frequency,
and worsened clinical course in those with a high burden of X4
variants [7].
In the ﬁrst phases of the infection, independently of the
route of transmission, early and massive viral replication
occurs in gut-associated lymphoid tissue, leading to irrevers-
ible mucosal CD4 T-cell depletion. A complex network of
HIV-1-target cells is established during this phase, leading to a
progressive ﬁlling of reservoirs and to viral dissemination in
the body [12].
There is growing evidence that compartmentalization may
be an early event during the natural history of HIV-1 infection
[13,14]. Some pathogenetic models suggest that a status of
immune hyperactivation represents one of the main predictors
of disease progression [15]. Recently, van Marle et al. [16]
showed discordant results for compartmentalization of virus
replication within different gut locations and peripheral blood
mononuclear cells (PBMC) of chronically infected patients
naive to antiretroviral therapy, depending on the genomic
region analysed (nef and pol). In another report on gut-asso-
ciated lymphoid tissue versus PBMC, compartmentalization of
viral quasispecies was highlighted on the basis of different drug
resistance-associated mutations [17]. In other studies, no
evidence of compartmentalization was observed between gut
and peripheral blood and even within different gut regions
(colon versus ileum) in chronically HIV-1-infected individuals
[18]. At the same time, evidence of cross-infection between
gut-associated lymphoid tissue and PBMC during combined
antiretroviral therapy (cART) has been suggested as a possible
mechanism for HIV persistence [19].
The present study was aimed at studying, by UDPS, the
tropism and compartmentalization of HIV-1 quasispecies in gut
and peripheral blood in cART-naive patients with early
infection compared with chronically infected patients, analysing
possible correlations between the presence of X4 variants and
the extent of immune activation.
Methods
Patients
Seventeen HIV-1 infected patients, for whom there was clinical
indication to perform a duodenal biopsy for diagnostic
purposes, were consecutively enrolled in the study. Eleven
subjects had a primary HIV infection, deﬁned by a negative or
indeterminate HIV-1 Western Blot with simultaneous positive
plasma HIV viraemia or by a positive HIV-1 antibody test
preceded by a documented negative test within the preceding
180 days (early infected patients); six patients had an HIV-1
infection documented for ≥3 years (chronic patients). At the
moment of biopsy, all patients with primary infection were in
Fiebig stage VI. At the same time-point, blood samples were
also collected (PBMC and plasma). All patients had acquired
HIV infection by a sexual route and were naive to cART at
enrolment. One early patients who underwent cART after
enrolment, was analysed at subsequent time-points (6 and
12 months from enrolment). The study was approved by the
Institutional Ethics Committee, and the patients agreed to
participate by signing an informed consent.
UDPS and data analysis
Total DNA extraction from PBMC and from duodenal biopsies
that were ﬁrst homogenized in cell lysis buffer (Qiagen, Hilden,
Germany) using a pestle, was performed using the extraction
kit ‘DNA blood’ (Qiagen). Plasma HIV-1 RNA was extracted
using the QIAamp Viral RNA kit (Qiagen). The number of
templates actually undergoing UDPS analysis was evaluated by
a commercial real-time PCR for HIV-1 RNA in plasma samples
(Abbott real-time HIV, Abbott Molecular Inc., Des Plaines, IL,
USA), and by a quantitative real-time PCR targeting the long
terminal repeat region for HIV DNA [20].
V3 ampliﬁcation was performed by nested PCR. Brieﬂy, two
rounds of 30 cycles (94°C for 2 min, 94°C for 30 s, annealing
at 60°C for 30 s, extension at 68°C for 30 s and ﬁnal
elongation at 68°C for 5 min) were carried out using a
proofreading DNA polymerase (Platinum Taq DNA Poly-
merase High Fidelity; Invitrogen, by Life Technologies, Monza,
Italy). First- and second-round primers were described in ref.
[7]. Nef ampliﬁcation was performed by a nested PCR, as
described in ref. [16]. For plasma samples, the ﬁrst round of
both env and nef included a one-step RT-PCR, using a Platinum
quality proofreading reverse transcriptase (Invitrogen). Unique
in-house-designed stretches of eight nucleotides (Multiplex
Identiﬁers), were used to tag each sample. To maximize the
genetic heterogeneity to be ampliﬁed and sequenced, for each
sample the amplicons from at least four replicate PCR were
pooled, representing, for viral RNA, the content of 1 mL of
plasma, and, for DNA, the content from 2 9 106 to 6 9 106
PBMC. To minimize the occurrence of artefacts attributable to
template re-sampling, a minimum of 1200 templates were
analysed by UDPS, on the basis of viral and proviral load
(Table 1).
The UDPS was carried out with the 454 Life Sciences
platform (GS-FLX, Roche Applied Science, Monza, Italy) as
described previously [7], using Titanium chemistry. For V3
amplicons the correction pipeline and the evaluation of
experimental error necessary to establish the sensitivity
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threshold have already been described [7]. Considering the
number of viral templates actually undergoing UDPS (at least
1200 copies) and the corrected error rate that we had
previously calculated for V3 (i.e. 0.058%, [7,8]), a sensitivity
threshold of 0.3% was adopted for this region—i.e. a value
exceeding by at least ﬁve-fold the error rate; all nucleotide
changes detected with a frequency ≤0.3% after the correction
pipeline were ignored. For nef amplicons, consensus reads
were directly extracted using GS AMPLICON VARIANT ANALYZER
software (v.2.5.3; Roche); each consensus read corresponds to
sets of individual reads that were collapsed into a single
representative read. In this case, the threshold of sensitivity
was conservatively set to 0.5%.
The nucleotide sequences resulting from the correction
pipeline (from nucleotide (nt) 7010 to nt 7332 of reference
HXB2 genome positions for V3 and from nt 8758 to nt 9454 of
reference HXB2 genome positions for nef amplicons), were
also analysed to establish genetic heterogeneity (diversity, i.e.
mean number of nucleotide substitutions/site) of the viral
quasispecies using DNADIST (F84 algorithm from Phylip
package). To construct individual phylogenetic trees, maximum
likelihood (ML) phylogenetic trees were inferred with the
MEGA program, using the GTR+G nucleotide model. Boot-
strap values >80% were considered signiﬁcant.
For co-receptor usage prediction, V3 sequences obtained
by UDPS were submitted to the genotypic predictor algorithm
geno2pheno [454] (http://454.geno2pheno.org/index.php). The
false-positive rate was set to 5.75%, corresponding to the
false-positive rate suggested for population sequencing of RNA
by retrospective re-analysis of the Maraviroc licensing studies
[21,22], and intra-patient X4 frequency was calculated for each
sample type.
Immune activation markers
Commercially available ELISA kits were used to quantify plasma
levels of sCD14 and soluble tumour necrosis factor receptor II
(sTNFRII; R&DSystems Europe, Abingdon, UK). Plasma samples
from 14 patients were available for this analysis. The samples
were diluted 1 : 200 and 1 : 20 for sCD14 and sTNFRII,
respectively, using the Calibrator Diluent provided in the kit,
including Triton X (ﬁnal concentration 0.1%), to produce
samples with values within the dynamic range of the assay.
Histological evaluation
Duodenal biopsy specimens obtained endoscopically were ﬁxed
in a 4% buffered formalin for 24 h, dehydrated and embedded in
parafﬁn. The tissueswere analysed on the basis ofmorphological
and immunohistochemical analysis. The villous/crypt ratio and
the numbers of lymphocytes in the intraepithelial region were
established. Staining for CD3 (Clone 2GV6) and CD4 (Clone SP
35)was carried out using a Ventana ES automatic immunostainer
(Ventana Medical System Inc., Tucson, AZ, USA). The sections
were counterstained with haematoxylin & eosin, and ten
randomly selected areas per slide were scored using the 209
objective with 100 enterocytes counted in each ﬁeld in the
surface epithelium on the top of the villi.
Statistical analysis
Mann–Whitney and Spearman rank correlation non-paramet-
ric tests were used as appropriate. For statistical calculation,
an X4 frequency equal to the sensitivity threshold (i.e. 0.3%)
was assigned to the X4-negative samples.
Results
Clinical features, genetic heterogeneity and X4 variants in
the viral quasispecies associated with gut and peripheral
blood
Demographic, clinical and virological characteristics of study
patients are reported in Table 1. Nadir CD4 T-cell counts
were signiﬁcantly lower (p 0.039), while median values of
plasma viral load, proviral load in PBMC and gut biopsy, sCD14
and sTNFRII were similar in patients with chronic infection
compared with early infection patients.
To evaluate genetic heterogeneity, genetic distances were
calculated from env V3 and nef sequences. UDPS analysis of the
V3 region provided a total of 69 080 edited sequences for
plasma HIV RNA, 82 210 for PBMC-associated proviral DNA
and 113 162 for gut biopsy proviral DNA. The UDPS analysis
of nef was performed on a subgroup of patients (in four early
patients the analysis was performed on all the three sample
types, whereas in eight early and in ﬁve chronic patients the





(n = 6) pb
Age (years) 33.0 (24.0–37.0) 39.5 (37.0–44.5) 0.050
Gender (M/F) 10/1 6/0 0.751
Days from diagnosis 40.0 (28.0–69.0) 568.0 (106.0–3402.0) 0.004
CD4 T (cell/lL) 563 (417–1251) 383 (77–548) 0.056
Nadir CD4 T (cell/lL) 414 (219–584) 350 (77–380) 0.040
Plasma viral load
(HIV-RNA Log copies/mL)








3.2 (2.8–4.2) 3.2 (2.9–3.6) 0.841
sCD14 (μg/mL) 1.9 (1.7–2.1) 2.2 (1.6–2.6) 0.679
sTNFRII (ng/mL) 5.1 (4.0–6.8) 6.0 (4.9–6.8) 0.371
Abbreviations: PBMC, peripheral blood mononuclear cells; sCD14, soluble CD14;
sTNFRII, soluble tumour necrosis factor receptor II.
aAll data are reported as median (interquartile range, IQR), except for gender,
where ratio M/F is reported.
bSigniﬁcance was calculated by Mann–Whitney non-parametric test or chi-squared
test, as appropriate. p values <0.05 were considered signiﬁcant.
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analysis was conducted only on plasma samples). The total
edited nef sequences were 5639 for plasma HIV, 3945 for
PBMC proviral DNA and 2014 for gut proviral DNA.
Considering all sample types, a direct correlation was
observed between V3 diversity and X4 frequency (r = 0.665, p
<0.001). An inverse correlation was observed between V3
diversity of plasma viral RNA and CD4 T-cell counts
(r = 0.661, p 0.005).
The distributions of intra-patient values of V3 genetic
diversity and of X4 frequencies in gut, PBMC and plasma from
early and chronic patients are shown in Fig. 1. Median values of
V3 diversity for all three sample types were lower in early
patients compared with chronic patients (Fig. 1a–c), reaching
statistical signiﬁcance for plasma HIV RNA values (median
values 0.003 versus 0.024 mean substitutions/site, p 0.011).
Consistent with V3 diversity, median values of nef diversity in
plasma HIV RNA were also signiﬁcantly lower in early patients
compared with chronic patients (0.010 versus 0.021, p 0.019,
not shown in the ﬁgure).
The proportion of patients harbouring X4 variants (as
either minor or predominant variants) in at least one
compartment tended to be lower in early versus chronic
patients (45% versus 67%); consistently, intrapatient frequen-
cies of X4 variants in the proviral DNA tended to be lower in
early compared with chronic patients (Fig. 1d–f), although not
reaching statistical signiﬁcance.
Considering immune activation markers, plasma levels of
sCD14 and sTNFRII were directly correlated (r = 0.729,
p 0.002). Of note, considering all 14 patients where the
activation markers could be evaluated, plasma levels of sCD14
were directly correlated with the X4 frequencies present in
circulating plasma RNA quasispecies (r = 0.602, p 0.023). No
correlation was observed between proviral load in gut biopsies




FIG. 1. HIV diversity and intra-patient
frequencies of X4 variants of V3 region in
gut and peripheral blood from patients
with early and chronic infections. The
genetic diversity of V3 (a–c) and
intra-patient frequencies of X4 variants
(d–f) in the three sample types (gut,
peripheral blood mononuclear cells and
plasma) from early and chronic patients
are reported. Bars indicate median values.
In panels d–f, dotted line represents the
sensitivity threshold for X4 frequency
(0.3%). Statistically signiﬁcant difference
between the two groups is indicated. [This
ﬁgure was corrected on 25/11/2013 after
original online publication 18/10/2013.
The title of panel C previously read
“Plasma proviral RNA”. This has been
amended.]
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O157–O166
O160 Clinical Microbiology and Infection, Volume 20 Number 3, March 2014 CMI
Compartmentalization of viral replication in early and
chronic patients
To analyse viral compartmentalization between gut and
peripheral blood, phylogenetic trees were constructed for
those patients who showed a genetic diversity >0.02 substi-
tutions/site in V3 region in at least one compartment (six early
and four chronic patients).
V3 compartmentalization of proviral quasispecies in gut and
PBMC proviral DNA was more pronounced in early than in
chronic patients (evident compartmentalization in ﬁve of six
early patients versus one of four chronic patients). In Fig. 2
the phylogenetic trees built on V3 and nef UDPS sequences
from two representative early patients (#1 and #2) are
shown; in Fig. 3 the V3 sequences from a representative
(a) (c)
(b) (d)
FIG. 2. Phylogenetic trees built with sequences from two representative patients with early infection(#1 and #2). The phylogenetic tree
constructed with V3 and nef sequences are reported in (a) and (b) for early patient #1, and in (c) and (d) for early patient #2, respectively. Only
bootstrap values >80% are indicated. Patient #1. (a) R5 proviral DNA sequences from peripheral blood mononuclear cells (PBMC) are shown in blue
(sequence name); R5 proviral DNA sequences from gut biopsy are shown in red (sequence name) whereas X4 sequences in orange (sequence name);
R5 sequences from plasma viral RNA are shown in green (sequence name). (b) Proviral DNA sequences from PBMC are shown in blue (sequence
name); proviral DNA sequences from gut biopsy are shown in red (sequence name); sequences from plasma viral RNA are shown in green (sequence
name). Patient #2. (c) R5 proviral DNA sequences from PBMC are shown in blue (sequence name) whereas X4 proviral DNA sequences in turquoise
(sequence name); R5 proviral DNA sequences from gut biopsy are shown in red (sequence name) whereas X4 proviral DNA sequences in orange
(sequence name); X4 sequences from plasma viral RNA are shown in light green (sequence name). (d) Proviral DNA sequences from PBMC are
shown in blue (sequence name); proviral DNA sequences from gut biopsy are shown in red (sequence name); sequences from plasma viral RNA are
shown in green (sequence name).
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chronic patient is shown. As can be seen in Fig. 2(a), in one
early patient the vast majority of viral quasispecies variants in
all three compartments are R5, and are grouped into two
well-deﬁned clusters, including either proviral PBMC DNA or
proviral gut DNA + plasma RNA. So, in this patient the
replicating viral components are originated presumably by the
proviral population from gut and not from PBMC. In this
patient only gut-associated proviral DNA harbours X4
variants, as minority quasispecies (0.58%). In Fig. 2(c), a strong
compartmentalization between gut and PBMC is shown for
another early patient, where the proportion between R5 and
X4 variants is reversed compared with the patient from
Fig. 2(a). In fact, replicating virions are essentially X4, and are
closely related to proviral genomes harboured by gut tissue,
with only a minimal contribution by the X4 genomes
harboured by PBMC. On the other hand, the vast majority
(97%) of PBMC variants displaying R5 characteristics do not
seem to contribute to replicating plasma viral RNA. The
phylogenetic trees built with nef sequences from the same
patients (Fig. 2b,d) strongly support the compartmentalization
highlighted by V3 analysis. The phylogenetic tree built with the
env sequences from one typical chronic patient (Fig. 3) clearly
shows intermixed viral quasispecies components from the
three compartments.
In one early patient, who started successful cART soon after
the ﬁrst sampling, it was possible to perform longitudinal
analysis over a period of 1 year. As shown in Fig. 4, HIV
proviral variants segregated in different clusters between
PBMC and gut at the time of early infection. At 6 months,
PBMC quasispecies included additional variants, corresponding
to time 0 (T0) gut clusters. After 1 year, gut/PBMC compart-
mentalization was no longer observed, with common clusters
present in both compartments, although with different
frequencies. The progressive loss of gut/PBMC compartmen-
FIG. 3. Phylogenetic tree built with V3
sequences from a representative patient
with chronic infection. R5 proviral DNA
sequences from peripheral blood
mononuclear cells are shown in blue
(sequence name) whereas X4 proviral
DNA sequences in turquoise (sequence
name); R5 proviral DNA sequences from
gut biopsy are shown in red (sequence
name) whereas X4 proviral DNA
sequences in orange (sequence name);
R5 sequences from plasma viral RNA are
shown in green (sequence name). Only
bootstrap values >80% are indicated.
FIG. 4. Longitudinal evaluation of V3 quasispecies compartmentalization during 1 year in one representative patient with early infection. (a–c)
Phylogenetic trees built with V3 sequences from patient #3 obtained at different time-points (T0, a; T6, b; T12, c) from different compartments.
Proviral DNA sequences from peripheral blood mononuclear cells (PBMC) are shown in turquoise (sequence name) at T0; in light blue (sequence
name) at T6; in dark blue (sequence name) at T12. Proviral DNA sequences from gut biopsy are shown in red (sequence name) at T0; in bordeaux
(sequence name) at T12. Sequences from plasma viral RNA are shown in light green (sequence name) at T0. X4 sequences are marked with an
asterisk. Individual clusters of variants are identiﬁed with a number. Only bootstrap values >80% are indicated. (d) Distribution of variants according
to individual clusters identiﬁed in (a–c). To highlight low frequency variants, the vertical axis scale has been censored to 12; individual frequency of
variants is indicated on each column. The colour code is the same used in (a–c); X4 frequencies are marked with an asterisk.
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talization was paralleled by the enrichment of X4 variants in
proviral DNA from both PBMC (from 4% to ≥90%) and gut
(from 1% to 23%), despite complete cART-driven suppression
of plasma viral load. It is noteworthy that at T0 the X4 variants
present in circulating RNA corresponded mainly to T0 PBMC
clusters, whereas R5 variants corresponded mainly to T0 gut
clusters.
Histological evaluation, conducted on a subgroup of patients
(two early and one chronic), suggested a trend towards a more
preserved anatomical structure of gut epithelium in early
versus chronic patients. Fig. 5(a,b) shows a nearly normal
mucosa from an early patient, with subtle reactive epithelial
changes: the epithelium is inﬁltrated by neutrophils with
inﬂammation in the lamina propria, without signiﬁcant loss of
villous architecture, and normal villous height to crypt depth
ratio of 3 : 1 (Fig. 5a). The total number of CD3+ intraepi-
thelial lymphocytes (IEL) was normal, with a ratio of about 20
lymphocytes per 100 epithelial cells and two CD4+ lympho-
cytes per 20 CD3+ IEL (Fig. 5b). In Fig. 5(c,d), the duodenal
mucosa from another early patient is shown, with normal
villous architecture (Fig. 5c), with 25 IEL per 100 epithelial cells
and three CD4+ lymphocytes per 20 CD3+ IEL (Fig. 5d). In
contrast, the duodenal mucosa sample from a chronic patient
(Fig. 5e,f) shows mild blunting of villi and elongated hypertro-
phic crypts (Fig. 5e). More than 29 CD3+ IEL per 100 epithelial
cells were counted, and CD4+ IELs were not detected (Fig. 5f).
Discussion
From this proof of concept study, based on ultrasensitive
evaluation of HIV quasispecies in two small groups of patients
(early versus chronic infection), the presence of X4 strains
appears to be common in all compartments at both stages of
infection. The presence of X4 variants in the gut is not
unexpected, as CXCR4 expression has been demonstrated on
both naive (CD45RO) and memory (CD45RO) CD4 T cells
from gut mucosa. In addition, X4 HIV isolates have been
reported to be able to actively replicate in these cells, although
to a lesser extent than R5 isolates [23,24]. Our ﬁndings also
suggest the accumulation of viral diversity during chronic




FIG. 5. Immunostaining of duodenal
biopsy from early and chronic patients
with anti-CD3 and anti-CD4. (a, c, e)
Immunostaining with anti-CD3 of
duodenal biopsy from two patients with
early infection (a, c) and one chronically
HIV-infected patient (e) (200 9, 100 9
and 100 9, respectively). (b, d, f)
Immunostaining with anti-CD4 of
duodenal biopsy from two patients with
early infection (b, b) and one chronically
HIV-infected patient (f) (400 9, 200 9
and 400 9, respectively).
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Interestingly, compartmentalization of viral quasispecies
between gut and peripheral blood was typically observed in
early patients. This ﬁnding suggests that gut compartmental-
ization of HIV quasispecies is an early event during the natural
history of the infection, as already reported for other body
compartments, such as central nervous system, possibly as a
consequence of divergent evolution of HIV lineages associated
with trafﬁcking of lymphomonocyte clones [26].
In contrast, an intermixed pattern of HIV quasispecies
distribution between peripheral blood and gut tissue was the
most frequent condition observed in chronic patients, sug-
gesting that during disease, progression compartmentalization
tends to be lost, in parallel with increased viral diversity and
X4 frequency. In fact, the longitudinal observation of one
patient during 1 year after primary infection strongly supports
this interpretation, showing progressive loss of gut/PBMC
compartmentalization, paralleled by increased X4 variant
frequency, despite effective suppression of plasma viraemia.
Lack of compartmentalization has been observed in chronic
patients under long-lasting effective cART [19]. In contrast
with these results, in another study based on patients on
prolonged suppressive cART, a clear segregation of plasma and
CD4 T-cell-derived viral sequences has been shown, with
low-level plasma HIV produced mostly by cells other than
CD4 T cells [27]. Interestingly, in this study the plasma
sequences obtained from two patients before and after
therapy interruption were apparently produced by the same
compartment, which was different from the circulating CD4 T
cells. The authors suggest that plasma viruses in patients on
long-term suppressive cART may be persistently released from
a cellular source yet to be identiﬁed, capable of spreading
quickly in vivo, accounting for the rapid rebound of plasma viral
loads after therapy interruption.
From the present study it is not possible to infer whether
the loss of quasispecies compartmentalization observed in
chronic patients was connected with the loss of integrity of gut
architecture, because histological evaluation of intestinal
biopsy was performed in only one chronic patient.
Another interesting ﬁnding from the present study is the
positive correlation betweenX4 variant frequency and extent of
immune activation assessed by indirect soluble markers (sCD14
levels). In a recent study, a direct correlation between proviral
load in rectosigmoid biopsies and plasma levels of a marker of
immune activation, i.e. LPS, has been observed in virologically
suppressed patients [28]; however, in the present study no
correlation between proviral load in gut biopsies and plasma
levels of sCD14 was observed. This apparent discrepancy may
be accounted for by the fact that in our study the immune
activation markers were evaluated in untreated patients.
More studies are needed to better understand the patho-
genetic signiﬁcance of early HIV quasispecies compartmental-
ization in the gut, plasma and peripheral mononuclear cells, the
role of immune activation on tropism switch and, ﬁnally, the
clinical signiﬁcance of the progressive intermixing of viral
variants in subsequent phases of the infection.
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